(Q53241629)

12 May 2018

title

Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients. (English)

1 reference

12 May 2018

0 references

1 reference

N Rösler

1

1 reference

12 May 2018

I Wichart

series ordinal

2

1 reference

12 May 2018

K A Jellinger

series ordinal

3

1 reference

12 May 2018

publication date

1 January 2001

1 reference

12 May 2018

Journal of Neural Transmission

published in

1 reference

12 May 2018

volume

108

1 reference

12 May 2018

issue

2

1 reference

12 May 2018

page(s)

231-246

1 reference

12 May 2018

https://scigraph.springernature.com/pub.10.1007/s007020170091

exact match

0 references

cites work

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

The genetics of Alzheimer disease: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

The role of APOE polymorphisms in late-onset dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Integrity of the blood-CSF barrier in dementia of Alzheimer type: CSF/serum ratios of albumin and IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Inflammatory pathogenesis in Alzheimer's disease: biological mechanisms and cognitive sequeli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Interleukin-6 secretion from human astrocytoma cells induced by substance P.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Tau protein and the neurofibrillary pathology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

CSF and serum concentrations of albumin and IgG in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

The integrity of the blood-brain barrier in Alzheimer's type and multi-infarct dementia evaluated by the study of albumin and IgG in serum and cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Substance P and neuropsychiatric disorders: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Relationship of interleukin-1 beta and beta 2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Blood-brain-barrier in a geriatric population: barrier function in degenerative and vascular dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Accuracy of clinical operational diagnostic criteria for Alzheimer's disease in relation to different pathological diagnostic protocols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Molecular genetics of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Longitudinal stability of CSF tau levels in Alzheimer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Neuropeptide changes in dementia: pathogenetic implications and diagnostic value

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS007020170091

Biological markers for the diagnosis of Alzheimer's disease.

21 January 2018

1 reference

12 December 2020

Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease--correlation with degree of cognitive impairment

1 reference

12 December 2020

Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid

1 reference

12 December 2020

Concentrations of amyloid-beta protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease

1 reference

12 December 2020

Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease.

1 reference

12 December 2020

Central nervous system IgG synthesis rates in Alzheimer disease: possible differences in early-onset and late-onset subgroups.

1 reference

12 December 2020

Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group

1 reference

12 December 2020

Serum levels of interleukin-6 and acute phase responses

1 reference

12 December 2020

Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients.

1 reference

12 December 2020

Neuroimmune mechanisms in Alzheimer disease pathogenesis

1 reference

12 December 2020

Intra-blood-brain-barrier synthesis of immunoglobulins in patients with dementia of the Alzheimer type.

1 reference

12 December 2020

Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.

1 reference

12 December 2020

Oligoclonal bands and blood--cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease: comparison with vascular dementia, major depression, and multiple sclerosis.

1 reference

12 December 2020

Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor rece

1 reference

12 December 2020

Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF

1 reference

12 December 2020

What is new in degenerative dementia disorders?

1 reference

12 December 2020

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

1 reference

12 December 2020

Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing.

1 reference

12 December 2020

On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases

1 reference

12 December 2020

Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures

1 reference

12 December 2020

Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease

1 reference

12 December 2020

Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia

1 reference

12 December 2020

Measurement of apolipoprotein E (apoE) in cerebrospinal fluid

1 reference

12 December 2020

The neuropathological diagnosis of Alzheimer disease.

1 reference

12 December 2020

The pathogenesis of senile plaques

1 reference

12 December 2020

Neurochemical abnormalities in Alzheimer's disease and Parkinson's disease--a comparative review

1 reference

12 December 2020

Identifiers

DOI

10.1007/S007020170091

1 reference

12 May 2018

PubMed ID

11314776

1 reference

12 May 2018